Qilu Pharmaceutical begins new era of high-content α avermectin

Date:07-04-2022

The Qixing Formulation Brand Operation Department of the Crop Protection Business Group of China's Qilu Pharmaceutical was founded on June 6, 2022, with its brand operation center based in Shanghai, to develop biopesticide-based advanced crop protection solutions.

Following the development concept of Independent Innovation + Strategic Technical Origination + Industry Cooperation, the Qixing Formulation Brand Operation Department will provide farmers with products at same prices but with better quality, and products with the same quality but at better prices. The company is preparing the launch of a number of formulations based on avermectin, spinosad and emamectin benzoate, highlighting Qilu Pharmaceutical’s development of avermectin and the start of the avermectin α value era. 

Technical advantages of Qilu’s avermectin technical

Avermectin technical is a mixture of eight homologies, where the homolog with highest yield and activity is B1a. However, B1a has an unsatisfactory twin brother, B1b, which is the least active. The ratio of B1a and B1b content is called α value, where the higher the ratio  the higher the B1a content, meaning better efficacy.

 

The ratio of avermectin produced by Qilu Pharmaceutical is B1a:B1b > 90:1, the highest B1a content in China. Qilu Pharmaceutical uses high-content α technical to manufacture avermectin compared to other vendors, increasing efficacy by at least by 10%, which enables formulations at various contents, including 10% SC, 5% SC, 5% ME and 5% EC.

Qilu Pharmaceutical’s production of ivermectin is backed up by three key technologies, which are strain resource-covered strains determining future potential and enabling continuous isolation and the screening of high-content α strains, which is a major advantage; genetic modification that adjusts genome to utilize the genetic potential of strains and promote more B1a gene expression; fermentation regulation allowing for the continuous exploration of fermentation conditions and the optimization of the optimal fermentation process, which promotes the synthesis of more B1a.

Data showed that Qilu Pharmaceutical’s annual avermectin capacity has reached 5,000 tons, becoming the world’s leading avermectin supplier.

Qilu’s advantage: Supply of spinosad technical

With a production capacity of 1,500 tons, Qilu Pharmaceutical is the world’s second leading  commercialized spinosad supplier, and is expected to become the world’s largest supplier.

One of its main products, Hanqingsu (spinosad 10% SC), contains high-content α technical and is produced in SC, which is safe and can be used for drone application. 

Qilu’s advantage: Supply of emamectin benzoate

Qilu Pharmaceutical’s emamectin benzoate capacity has reached 1,000 tons annually, making it the leading emamectin benzoate manufacturer. The company produces high-purity and high-content α value emamectin benzoate technical.

Another major product, Hongruida (emamectin benzoate 5% ME), which is registered for preventing and controlling rice leaf borer and packaged at 100ml and 1000ml, has high-content α technical, resulting in increased efficacy with the same amount used. It is made using nano-formulation technology, which facilitates faster penetration when mixed with water without turning white.

As a global leading supplier of avermectin and emamectin benzoate, Qilu Pharmaceutical is committed to offering green and sustainable agricultural crop protection products, through the use of advanced biotechnology, allowing farmers to share its technological achievements.